EpiVax_Oncology_NYAS_08May19_35Wx25H
Results for "ancer"
Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines
EpiVax_Oncology_TRI-CON_CT26_04Mar19_32w44h
Frontiers in Cancer Immunotherapy May 14th-15th, 2019
Frontiers in Cancer Immunotherapy Symposium Tuesday, May 14th - Wednesday, May 15th Registration starts at 8:30A.M. on Tuesday The New York Academy of Sciences 7 World Trade Center New York City, New York Meet EpiVax Oncology's CEO/Co-Founder, Gad Berdugo, and Interim...
EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019
THIS ORIGINAL ARTICLE WAS PUBLISHED IN PR NEWSWIRE. LINK TO THE ORIGINAL ARTICLE CAN BE FOUND HERE. NEW YORK, March 25, 2019 /PRNewswire/ -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an...
American Association for Cancer Research Meeting March 29th-April 3rd, 2019 (Updated)
American Association for Cancer Research (AACR) Annual MeetingFriday, March 29th - Wednesday, April 3rdGeorgia World Congress CenterAtlanta, GeorgiaThank you to everyone who attended Dr. Richard's presentation at AACR 2019. We hope you learned something new! In case...
Integrated Approaches for Design of Precision Cancer Immunotherapies: Selection of Class I and Class II T cell Neo-Epitopes and Removal Treg Epitopes
2018 Design of Cancer Immunotherapies - Selection of Neo-Epitopes, Removal of Tregitopes
Ancer: An Innovative Cancer Neoantigen Prediction System
2017 Ancer An Innovative Cancer Neoantigen Prediction System
From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses
EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H
Disease Status Explained by Neo-epitopes with Low Potential for Activating Regulatory T cells: an Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer
EpiVax_poster_Disease Status Explained by Neo-Epitopes with Low Potential for Activating Regulatory T Cells
Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer: Non-Self-Like Neo-epitopes as a Prognostic Biomarker
EpiVax_Ancer_CICON_Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer_26Sep18